Anti-PDCD1/ PD-1/ CD279 monoclonal antibody

Anti-PDCD1/ PD-1/ CD279 antibody for FACS & in-vivo assay

Target products collectionGo to PD-1/PDCD1 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)


Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-T59631-Ab-1/ GM-Tg-hg-T59631-Ab-2Anti-Human PD-1/PDCD1 monoclonal antibodyHuman
GM-Tg-rg-T59631-Ab-1/ GM-Tg-rg-T59631-Ab-2Anti-Rat PD-1/PDCD1 monoclonal antibodyRat
GM-Tg-mg-T59631-Ab-1/ GM-Tg-mg-T59631-Ab-2Anti-Mouse PD-1/PDCD1 monoclonal antibodyMouse
GM-Tg-cynog-T59631-Ab-1/ GM-Tg-cynog-T59631-Ab-2Anti-Cynomolgus/ Rhesus macaque PD-1/PDCD1 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-T59631-Ab-1/ GM-Tg-felg-T59631-Ab-2Anti-Feline PD-1/PDCD1 monoclonal antibodyFeline
GM-Tg-cang-T59631-Ab-1/ GM-Tg-cang-T59631-Ab-2Anti-Canine PD-1/PDCD1 monoclonal antibodyCanine
GM-Tg-bovg-T59631-Ab-1/ GM-Tg-bovg-T59631-Ab-2Anti-Bovine PD-1/PDCD1 monoclonal antibodyBovine
GM-Tg-equg-T59631-Ab-1/ GM-Tg-equg-T59631-Ab-2Anti-Equine PD-1/PDCD1 monoclonal antibodyEquine

Size: 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-T59631-Ab-1/ GM-Tg-hg-T59631-Ab-2; GM-Tg-rg-T59631-Ab-1/ GM-Tg-rg-T59631-Ab-2;
GM-Tg-mg-T59631-Ab-1/ GM-Tg-mg-T59631-Ab-2; GM-Tg-cynog-T59631-Ab-1/ GM-Tg-cynog-T59631-Ab-2;
GM-Tg-felg-T59631-Ab-1/ GM-Tg-felg-T59631-Ab-2; GM-Tg-cang-T59631-Ab-1/ GM-Tg-cang-T59631-Ab-2;
GM-Tg-bovg-T59631-Ab-1/ GM-Tg-bovg-T59631-Ab-2; GM-Tg-equg-T59631-Ab-1/ GM-Tg-equg-T59631-Ab-2
Products NameAnti-PD-1/PDCD1 monoclonal antibody
Formatmab
Target NamePD-1
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody, Therapeutics Target antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)
IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-PD-1 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation Lyophilized from sterile PBS, PH 7.4
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    BiosimilarGMP-Bios-ab-435Pre-Made Pembrolizumab biosimilar, Whole mAb, Anti-PDCD1/PD-1 Antibody: Anti-CD279/PD1/SLEB2/hSLE1 therapeutic antibody
    BiosimilarGMP-Bios-ab-101Pre-Made Cetrelimab biosimilar, Whole mAb, Anti-PDCD1/PD-1 Antibody: Anti-CD279/PD1/SLEB2/hSLE1 therapeutic antibody
    BiosimilarGMP-Bios-ab-088Pre-Made Cadonilimab biosimilar, Bispecific Mixed mAb and scFv, Anti-PDCD1/PD-1;CTLA4/CTLA-4 antibody: Anti-CD279/PD1/SLEB2/hPD-1/hPD-l/hSLE1;CD/GSE/GRD4/ALPS5/CD152/IDDM12/CELIAC3 therapeutic antibody
    BiosimilarGMP-Bios-ab-679Pre-Made Lorigerlimab biosimilar, Whole mAb, Anti-PDCD1/PD-1;CTLA4/CTLA-4 Antibody: Anti-CD279/PD1/SLEB2/hPD-1/hPD-l/hSLE1;CD/GSE/GRD4/ALPS5/CD152/IDDM12/CELIAC3 therapeutic antibody
    BiosimilarGMP-Bios-INN-1058Pre-Made Zimbirelimab Biosimilar, Whole Mab, Anti-PDCD1/PD-1 Antibody: Anti-CD279/PD1/SLEB2/hSLE1 therapeutic antibody
    BiosimilarGMP-Bios-ab-581Pre-Made Tislelizumab biosimilar, Whole mAb, Anti-PDCD1/PD-1 Antibody: Anti-CD279/PD1/SLEB2/hSLE1 therapeutic antibody
    BiosimilarGMP-Bios-ab-381Pre-Made Nivolumab biosimilar, Whole mAb, Anti-PDCD1/PD-1 Antibody: Anti-CD279/PD1/SLEB2/hSLE1 therapeutic antibody
    BiosimilarGMP-Bios-ab-459Pre-Made Pucotenlimab biosimilar, Whole mAb, Anti-PDCD1/PD-1 Antibody: Anti-CD279/PD1/SLEB2/hSLE1 therapeutic antibody
    BiosimilarGMP-Bios-ab-044Pre-Made Balstilimab biosimilar, Whole mAb, Anti-PDCD1/PD-1 Antibody: Anti-CD279/PD1/SLEB2/hSLE1 therapeutic antibody
    BiosimilarGMP-Bios-ab-692Pre-Made Rulonilimab biosimilar, Whole mAb, Anti-PDCD1/PD-1 Antibody: Anti-CD279/PD1/SLEB2/hSLE1 therapeutic antibody
    BiosimilarGMP-Bios-ab-648Pre-Made Zimberelimab biosimilar, Whole mAb, Anti-PDCD1/PD-1 Antibody: Anti-CD279/PD1/SLEB2/hSLE1 therapeutic antibody
    BiosimilarGMP-Bios-ab-240Pre-Made Geptanolimab biosimilar, Whole mAb, Anti-PDCD1/PD-1 Antibody: Anti-CD279/PD1/SLEB2/hSLE1 therapeutic antibody
    BiosimilarGMP-Bios-ab-090Pre-Made Camrelizumab biosimilar, Whole mAb, Anti-PDCD1/PD-1 Antibody: Anti-CD279/PD1/SLEB2/hSLE1 therapeutic antibody
    BiosimilarGMP-Bios-ab-442Pre-Made Pimivalimab biosimilar, Whole mAb, Anti-PDCD1/PD-1 Antibody: Anti-CD279/PD1/SLEB2/hSLE1 therapeutic antibody
    BiosimilarGMP-Bios-ab-644Pre-Made Zeluvalimab biosimilar, Whole mAb, Anti-PDCD1/PD-1 Antibody: Anti-CD279/PD1/SLEB2/hSLE1 therapeutic antibody
    BiosimilarGMP-Bios-ab-508Pre-Made Sasanlimab biosimilar, Whole mAb, Anti-PDCD1/PD-1 Antibody: Anti-CD279/PD1/SLEB2/hSLE1 therapeutic antibody
    BiosimilarGMP-Bios-ab-531Pre-Made Spartalizumab biosimilar, Whole mAb, Anti-PDCD1/PD-1 Antibody: Anti-CD279/PD1/SLEB2/hSLE1 therapeutic antibody
    BiosimilarGMP-Bios-ab-458Pre-Made Prolgolimab biosimilar, Whole mAb, Anti-PDCD1/PD-1 Antibody: Anti-CD279/PD1/SLEB2/hSLE1 therapeutic antibody
    BiosimilarGMP-Bios-ab-631Pre-Made Vudalimab biosimilar, Bispecific Mixed mAb and scFv, Anti-CTLA4/CTLA-4;PDCD1/PD-1 Antibody: Anti-CD/GSE/GRD4/ALPS5/CD152/IDDM12/CELIAC3;CD279/SLEB2/hPD-1/hPD-l/hSLE1 therapeutic antibody
    BiosimilarGMP-Bios-ab-523Pre-Made Sintilimab biosimilar, Whole mAb, Anti-PDCD1/PD-1 Antibody: Anti-CD279/PD1/SLEB2/hSLE1 therapeutic antibody
    BiosimilarGMP-Bios-ab-587Pre-Made Toripalimab biosimilar, Whole mAb, Anti-PDCD1/PD-1 Antibody: Anti-CD279/PD1/SLEB2/hSLE1 therapeutic antibody
    BiosimilarGMP-Bios-ab-436Pre-Made Penpulimab biosimilar, Whole mAb, Anti-PDCD1/PD-1 Antibody: Anti-CD279/PD1/SLEB2/hSLE1 therapeutic antibody
    BiosimilarGMP-Bios-ab-667Pre-Made Fidasimtamab biosimilar, Whole mAb, Anti-PDCD1/PD-1;ERBB2/HER2 Antibody: Anti-CD279/PD1/SLEB2/hSLE1;CD340/neu/MLN 19/NEU/NGL/TKR1/VSCN2 therapeutic antibody
    BiosimilarGMP-Bios-ab-672Pre-Made Iparomlimab biosimilar, Whole mAb, Anti-PDCD1/PD-1 Antibody: Anti-CD279/PD1/SLEB2/hSLE1 therapeutic antibody
    BiosimilarGMP-Bios-ab-154Pre-Made Dostarlimab biosimilar, Whole mAb, Anti-PDCD1/PD-1 Antibody: Anti-CD279/PD1/SLEB2/hSLE1 therapeutic antibody
    BiosimilarGMP-Bios-ab-097Pre-Made Cemiplimab biosimilar, Whole mAb, Anti-PDCD1/PD-1 Antibody: Anti-CD279/PD1/SLEB2/hSLE1 therapeutic antibody
    BiosimilarGMP-Bios-ab-441Pre-Made Pidilizumab biosimilar, Whole mAb, Anti-PDCD1/PD-1 Antibody: Anti-CD279/PD1/SLEB2/hSLE1 therapeutic antibody
    BiosimilarGMP-Bios-ab-287Pre-Made Izuralimab biosimilar, Bispecific Mixed mAb and scFv, Anti-ICOS;PDCD1/PD-1 antibody: Anti-AILIM/CD278/CVID1;CD279/SLEB2/hPD-1/hPD-l/hSLE1 therapeutic antibody
    BiosimilarGMP-Bios-ab-480Pre-Made Retifanlimab biosimilar, Whole mAb, Anti-PDCD1/PD-1 Antibody: Anti-CD279/PD1/SLEB2/hSLE1 therapeutic antibody
    BiosimilarGMP-Bios-ab-556Pre-Made Tebotelimab biosimilar, Bispecific scFv with Crossover, Anti-PDCD1/PD-1;LAG3 Antibody: Anti-CD279/PD1/SLEB2/hPD-1/hPD-l/hSLE1;CD223 therapeutic antibody
    BiosimilarGMP-Bios-ab-292Pre-Made Lambrolizumab biosimilar, Whole mAb, Anti-PDCD1/PD-1 Antibody: Anti-CD279/PD1/SLEB2/hSLE1 therapeutic antibody
    BiosimilarGMP-Bios-ab-515Pre-Made Serplulimab biosimilar, Whole mAb, Anti-PDCD1/PD-1 Antibody: Anti-CD279/PD1/SLEB2/hSLE1 therapeutic antibody
    BiosimilarGMP-Bios-ab-085Pre-Made Budigalimab biosimilar, Whole mAb, Anti-PDCD1/PD-1 Antibody: Anti-CD279/PD1/SLEB2/hSLE1 therapeutic antibody
    BiosimilarGMP-Bios-ab-684Pre-Made Nofazinlimab biosimilar, Whole mAb, Anti-PDCD1/PD-1 Antibody: Anti-CD279/PD1/SLEB2/hSLE1 therapeutic antibody
    BiosimilarGMP-Bios-ab-215Pre-Made Finotonlimab biosimilar, Whole mAb, Anti-PDCD1/PD-1 Antibody: Anti-CD279/PD1/SLEB2/hSLE1 therapeutic antibody
    BiosimilarGMP-Bios-ab-203Pre-Made Ezabenlimab biosimilar, Whole mAb, Anti-PDCD1/PD-1 Antibody: Anti-CD279/PD1/SLEB2/hSLE1 therapeutic antibody
    Target AntigenProducts DevelopingMulti-species PDCD1/ PD-1/ CD279 VLP (virus-like particle) (Products Developing)
    ORF Viral VectorpGMLV000228human PDCD1 Lentivirus plasmid
    ORF Viral VectorpGMLP004799human PDCD1 Lentivirus plasmid
    ORF Viral VectorpGMLV000709human PDCD1 Lentivirus plasmid
    ORF Viral VectorvGMLV000709human PDCD1 Lentivirus particle
    ORF Viral VectorpGMLV000813human PDCD1 Lentivirus plasmid
    ORF Viral VectorvGMLV000696human PDCD1 Lentivirus particle
    ORF Viral VectorpGMLV000696human PDCD1 Lentivirus plasmid
    ORF Viral VectorvGMLV000228human PDCD1 Lentivirus particle
    ORF Viral VectorvGMLV000813human PDCD1 Lentivirus particle
    ORF Viral VectorvGMLP004799human PDCD1 Lentivirus particle
    ORF Viral VectorpGMLV000162mouse Pdcd1 Lentivirus plasmid
    ORF Viral VectorvGMLV000162mouse Pdcd1 Lentivirus particle


    Target information

    Target IDGM-T59631
    Target NamePD-1
    Gene ID5133,18566,301626,100135775,486213,100135770,613842,100067948
    Gene Symbol and SynonymsCD279,hPD-1,hPD-l,hSLE1,Ly101,PD-1,PD1,Pdc1,PDCD1,SLEB2
    Uniprot AccessionQ15116
    Uniprot Entry NamePDCD1_HUMAN
    Protein Sub-locationTransmembrane Protein
    CategoryTherapeutics Target, Immuno-oncology Target, INN Index
    DiseaseCancer
    Gene EnsemblENSG00000188389
    Target ClassificationCheckpoint-Immuno Oncology, Tumor-associated antigen (TAA)

    The target: PD-1, gene name: PDCD1, also named as CD279, PD-1, PD1, SLEB2, hPD-1, hPD-l, hSLE1. Programmed cell death protein 1 (PDCD1) is an immune-inhibitory receptor expressed in activated T cells; it is involved in the regulation of T-cell functions, including those of effector CD8+ T cells. In addition, this protein can also promote the differentiation of CD4+ T cells into T regulatory cells. PDCD1 is expressed in many types of tumors including melanomas, and has demonstrated to play a role in anti-tumor immunity. Moreover, this protein has been shown to be involved in safeguarding against autoimmunity, however, it can also contribute to the inhibition of effective anti-tumor and anti-microbial immunity. [provided by RefSeq, Aug 2020].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.